Detalhe da pesquisa
1.
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
Lancet Oncol
; 23(5): 625-635, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35405088
2.
Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.
Breast Cancer Res
; 24(1): 58, 2022 09 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36056374
3.
The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS C.
Br J Cancer
; 126(12): 1715-1724, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35194193
4.
Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial.
Breast Cancer Res
; 22(1): 47, 2020 05 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-32408905
5.
Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial.
Int J Cancer
; 146(1): 262-271, 2020 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31162838
6.
Differential impact of prognostic parameters in hormone receptor-positive lobular breast cancer.
Cancer
; 126(22): 4847-4858, 2020 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32780421
7.
Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Breast Cancer Res Treat
; 175(1): 265-266, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30632020
8.
Lobular carcinoma in situ and invasive lobular breast cancer are characterized by enhanced expression of transcription factor AP-2ß.
Lab Invest
; 98(1): 117-129, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29035379
9.
Use of single-view digital breast tomosynthesis (DBT) and ultrasound vs. additional views and ultrasound for the assessment of screen-detected abnormalities: German multi-reader study.
Acta Radiol
; 59(7): 782-788, 2018 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-28929783
10.
Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Breast Cancer Res Treat
; 165(3): 573-583, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28664507
11.
BRCA1-like profile predicts benefit of tandem high dose epirubicin-cyclophospamide-thiotepa in high risk breast cancer patients randomized in the WSG-AM01 trial.
Int J Cancer
; 139(4): 882-9, 2016 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26946057
12.
Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial.
Breast Cancer Res Treat
; 150(2): 279-88, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25721604
13.
Evaluation of the Impact of Adaptive Progressive Supervised Resistance Training on Strength and Quality of Life in Patients with Breast Cancer During Chemotherapy: The VALESCO Study.
Oncol Res Treat
; 2024 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38714178
14.
Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancer.
Breast Cancer Res Treat
; 138(3): 839-50, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23568480
15.
Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapy.
Cancer Treat Rev
; 121: 102631, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37862832
16.
PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant.
Trials
; 24(1): 338, 2023 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37198674
17.
Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical Trial.
JAMA Oncol
; 9(7): 946-954, 2023 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37166817
18.
De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial.
J Clin Oncol
; 41(22): 3796-3804, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36809046
19.
Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR- Trial.
Clin Cancer Res
; 29(4): 805-814, 2023 02 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36441798
20.
Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer.
J Clin Oncol
; 40(23): 2557-2567, 2022 08 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35404683